Deals In Depth: October 2012
In a deal valued at $272 million, AZ got exclusive global rights to Ardelyx’s NHE3 program. Pfizer exercised an option to buy spec pharma NextWave for $255 million up front. Biophama companies raised almost $2 billion in October propelled by public offerings. Early venture rounds dominated device financing, which totaled $193 million.
You may also be interested in...
There is a much-acknowledged urgency to ensure medtech products are certified as fast as possible, with fears persisting that delays will result in notified body bottlenecks and product shortages.
The diagnostics company has secured $10m from the foundation to develop a biomarker test for Parkinson’s disease.
Generics Bulletin previews the most noteworthy and anticipated events for December 2023.